325P A Phase II, Open-Label, Single-Center Study of QL1706 Plus Platinum Doublet Chemotherapy with or Without Bevacizumab As First-Line Treatment in Patients with Advanced NSCLC: Data from EGFR Wild-Type Cohort
Annals of oncology(2022)
AI 理解论文
溯源树
样例

生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要